Pharmaceutical lobbying in Brazil: a missing topic in the public health research agenda
ABSTRACT In the US, where registration of lobbyists is mandatory, the pharmaceutical industry and private health-care providers spend huge amounts of money seeking to influence health policies and government decisions. In Brazil, where lobbying lacks transparency, there is virtually no data on drug...
Main Author: | Francisco José Roma Paumgartten |
---|---|
Format: | Article |
Language: | English |
Published: |
Universidade de São Paulo
|
Series: | Revista de Saúde Pública |
Subjects: | |
Online Access: | http://www.scielosp.org/scielo.php?script=sci_arttext&pid=S0034-89102016000200604&lng=en&tlng=en |
Similar Items
-
Investigating the landscape of US orphan product approvals
by: Kathleen L. Miller, et al.
Published: (2018-10-01) -
Evidence supporting regulatory-decision making on orphan medicinal products authorisation in Europe: methodological uncertainties
by: Caridad Pontes, et al.
Published: (2018-11-01) -
Development and Use of Gene Therapy Orphan Drugs—Ethical Needs for a Broader Cooperation Between the Pharmaceutical Industry and Society
by: Sandor Kerpel-Fronius, et al.
Published: (2020-12-01) -
Influence of European Market Dynamics on Biosimilars Market Share
by: Diogo Pires, et al.
Published: (2016-10-01) -
Analysis of patient access to orphan drugs in Turkey
by: Güvenç Koçkaya, et al.
Published: (2021-02-01)